- Home
- PRME
PRME
Prime Medicine Inc.
as 11-21-2024 4:00pm EST
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 424.9M | IPO Year: | 2022 |
| Target Price: | $13.86 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.85 - $9.86 | Next Earning Date: | 11-12-2024 |
| Revenue: | $800,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 21.23% |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
GlobeNewswire
9 days ago
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
15 days ago
Prime Medicine to Participate in Upcoming Investor Conferences
Motley Fool
24 days ago
12 High-Growth Stocks That Could Deliver Parabolic Returns
GlobeNewswire
a month ago
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
Motley Fool
a month ago
Why I Keep Buying These 14 Incredible Growth Stocks
GlobeNewswire
a month ago
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
Zacks
2 months ago
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.